A.F.H. Stalenhoef
- Surgery top 2%
- Endocrinology, Diabetes and Metabolism top 2%
- Cardiology and Cardiovascular Medicine top 5%
- Cancer Research top 5%
- Molecular Biology
- Co-authors
- Pierre N.M. DemackerSanne van WissenM van Linde-Sibenius TripTJ SmildeP.M.J. StuytJohn P. KaneR J HavelA. van ‘t Laar
- Topics
- Lipoproteins and Cardiovascular Health (20 papers)Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers)Cancer, Lipids, and Metabolism (10 papers)
- Partner nations
- NetherlandsUnited StatesVietnam
In The Last Decade
A.F.H. Stalenhoef
42 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Surgery 1.2k
- Endocrinology, Diabetes and Metabolism 777
- Cardiology and Cardiovascular Medicine 590
- Cancer Research 380
- Molecular Biology 350
Countries citing papers authored by A.F.H. Stalenhoef
This map shows the geographic impact of A.F.H. Stalenhoef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.F.H. Stalenhoef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.F.H. Stalenhoef more than expected).
Fields of papers citing papers by A.F.H. Stalenhoef
This network shows the impact of papers produced by A.F.H. Stalenhoef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.F.H. Stalenhoef. The network helps show where A.F.H. Stalenhoef may publish in the future.
Co-authorship network of co-authors of A.F.H. Stalenhoef
This figure shows the co-authorship network connecting the top 25 collaborators of A.F.H. Stalenhoef. A scholar is included among the top collaborators of A.F.H. Stalenhoef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.F.H. Stalenhoef. A.F.H. Stalenhoef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008) | 10 |
| 2 | The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. | 46 |
| 3 | 13 | |
| 4 | 25 | |
| 5 | Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trialbreakdown → | 704 |
| 6 | 76 | |
| 7 | 7 | |
| 8 | 144 | |
| 9 | 21 | |
| 10 | 188 | |
| 11 | 84 | |
| 12 | 26 | |
| 13 | 75 | |
| 14 | 31 | |
| 15 | 13 | |
| 16 | Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia). | 11 |
| 17 | 48 | |
| 18 | 17 | |
| 19 | 7 | |
| 20 | 22 |
About A.F.H. Stalenhoef
A.F.H. Stalenhoef is a scholar working on Endocrinology, Diabetes and Metabolism, Cancer Research and Surgery, having authored 44 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cancer, Lipids, and Metabolism (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (777 citations), Surgery (1.2k citations) and Biochemistry (167 citations). A.F.H. Stalenhoef has collaborated with scholars based in Netherlands, United States and Vietnam. Frequent co-authors include Pierre N.M. Demacker, Sanne van Wissen, M van Linde-Sibenius Trip, TJ Smilde, P.M.J. Stuyt, John P. Kane, R J Havel, A. van ‘t Laar, Mihai G. Netea and Bart Jan Kullberg. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.